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this comparison that tests the TasP hypothesis in PopART and that is now threatened to fail because of insufficient power (Table 1) . If WHO follows the United States [10, 11] in recommending immediate ART initiation for all HIV-infected people in the 2015 WHO ART guidelines, PopART will face the even larger threat of completely losing the Arm A versus B comparison [12] .
In contrast to the Arm A versus B comparison, the difference between Arms A and C in PopART is the effect of an extensive HIV combination prevention package ("the full intervention" [9] ), which includes immediate HIV treatment but also many other interventions: male circumcision, condom promotion, home-based behavioural HIV risk-reduction counselling, home-based HIV testing and referral to HIV treatment and care, home-based screening for sexually transmitted infections and referral for treatment, home-based screening for tuberculosis and referral for treatment, home-based identification of pregnant women and encouragement to attend antenatal care, and encouragement to access prevention of mother-to-child transmission services for pregnant women who test HIVpositive [9] .
If the PopART combination prevention package is shown to be effective, any subset of interventions in the package-which may or may not include TasP-could be responsible for the effect, and we cannot know which. Importantly, based on this comparison it is impossible to rule out that any significant effect is due entirely to those interventions in the package that have already been firmly established to be effective in preventing HIV, such as male circumcision [13] [14] [15] . The comparison of PopART Arm A versus C is thus not a valid test of the TasP hypothesis (Table 1) .
Given our shared interest in testing TasP, we are glad to read that Hayes and colleagues broadly endorse two of our proposals: to increase the power to test the TasP hypothesis by pooling data across trials and to consider randomised stepped-wedge scale-up of TasP as an additional strategy to establish TasP effectiveness. 
